Clinical Study

A Phase II Randomized Controlled Trial Of Genomically Directed Therapy After Preoperative Chemotherapy In Patients With Triple Negative Breast Cance

Posted Date: May 15, 2019

  • Investigator: Neetu Radhakrishnan
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to compare any good and bad effects of using a Food and Drug Administration (FDA)-approved drug selected based on the identification of genetic differences in your tumor to being treated using the standard approach. The standard approach may be surveillance, or additiona

Criteria:

You Are Being Asked To Take Part In This Research Study Because You Are At Least 18 Years Of Age And

Keywords:

Targetted Therapy, Triple Negative Brea, Poor Response To Neo, Adjuvant Therapy, Molecular Markers

For More Information:

Barbara Burke
5135840238
burkeb@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.